Wang, Sheng-Min
Kang, Dong Woo
Um, Yoo Hyun
Kim, Sunghwan
Lee, Chang Uk
Scheltens, Philip
Lim, Hyun Kook
Funding for this research was provided by:
Peoplebio inc
National Research Foundation of Korea (No. 2022R1A2C1093215)
Korea Dementia Research Center (HU22C0011)
Article History
Received: 6 April 2023
Accepted: 26 January 2024
First Online: 11 March 2024
Declarations
:
: The study was conducted in accordance with ethical and safety guidelines set forth by the Institutional Review Board of Yeouido St. Mary’s Hospital, The Catholic University of Korea (IRB number: SC21TISI0017), and all subjects provided written informed consent.
: Not applicable.
: The sponsors had no role in the design, execution, interpretation, or writing of this manuscript. Dr. Scheltens is a full-time employee of EQT Life Sciences (formerly LSP) and is a Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell, and Green Valley. Within his university, he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama, phase 2 study of UCB, and co-chair of the phase 3 study with NOVO-Nordisk. Until November 2022, he acted as chair of the EU steering committee of the phase 2b program of Vivoryon and the phase 2b study of Novartis Cardiology.